Drug Testing and Analysis
October 29, 2020
Klára Gotvaldová, Kateřina Hájková, Jan Borovička et al.
69 citations
Psilocybin, psilocin, baeocystin, norbaeocystin, and aeruginascin are tryptamines structurally similar to serotonin. Psilocybin and its active metabolite psilocin are known for psychoactive effects and occur in most Psilocybe fungi. Freshly cultivated Psilocybe cubensis fruit bodies were used to monitor stability under various storage and processing conditions. Mycelium and individual parts (caps, stipes, basidiospores) were examined via ultra-high-performance liquid chromatography-mass spectrometry. No tryptamines were detected in basidiospores; only psilocin was present at 0.47 wt.% in mycelium. Stipes contained about half the tryptamine alkaloids (0.52 wt.%) compared to caps (1.03 wt.%), but results were not statistically significant due to high variability. Highest degradation occurred in fresh mushrooms stored at -80°C; lowest decay in dried biomass stored in dark at room temperature.
International Journal of Molecular Sciences
November 15, 2022
Klára Gotvaldová, Jan Borovička, Kateřina Hájková et al.
50 citations
Wild mushrooms that contain psilocybin also carry several other tryptamine alkaloids in highly variable concentrations, making their effects unpredictable compared to pure psilocybin. Using ultra-high performance liquid chromatography with tandem mass spectrometry, researchers measured psilocybin, psilocin, baeocystin, norbaeocystin, and aeruginascin in 226 fruiting bodies from 82 collections across seven genera. Psilocybe species had the highest psilocybin and psilocin levels, but no tryptamines were detected in Psilocybe fuscofulva or Psilocybe fimetaria. For many species, concentrations of baeocystin, norbaeocystin, and aeruginascin were reported for the first time. The extreme variability in tryptamine content poses a risk of overdose for consumers and complicates interpretation of medicinal effects compared to chemically pure psilocybin.
Progress in neuro-psychopharmacology & biological psychiatry
July 5, 2025
Hynek Danda, Kristýna Mazochová, Klára Šíchová et al.
1 citation
Baeocystin, a compound found in psychoactive mushrooms, has minimal to no behavioral effects in rats, likely because it poorly crosses the blood-brain barrier. After subcutaneous doses of 1.25 or 5 mg/kg, baeocystin and its metabolite norpsilocin showed very limited brain penetration. Consistent with this, the compound had no significant effects on locomotor activity, exploratory behavior, anxiety-like responses, or sensorimotor gating in Wistar rats. The findings suggest baeocystin's negligible neurobiological and psychedelic activity is due to its poor permeability across the blood-brain barrier.
The International Journal of Neuropsychopharmacology
February 1, 2025
Martin Kuchař, Klara Gotwaldova, Jan Borovička et al.
1 citation
Tryptamine concentrations in psychotropic mushrooms vary enormously, which may alter medicinal effects compared to chemically pure psilocybin. Storage conditions strongly affect alkaloid decay: the greatest degradation occurred in fresh mushrooms stored at −80°C, while the least decay was seen in dried biomass kept in the dark at room temperature. The study measured psilocybin, psilocin, baeocystin, norbaeocystin, and aeruginascin in a large sample set of mushroom genera, using freshly cultivated Psilocybe cubensis fruit bodies for stability monitoring, and analyzed mycelium and individual fruiting body parts with validated UHPLC-MS/MS.
Addiction Biology
March 1, 2026
Isis Koutrouli, Vojtěch Brejtr, Marek Schwendt et al.
Psilocybin and ibogaine, given in a dose-escalation protocol, facilitated extinction learning in male rats that had self-administered cocaine. Psilocybin reduced active lever pressing one day after the second dose, with a nonsignificant reduction after the first dose; ibogaine significantly reduced pressing even after the first administration. Neither drug significantly altered cue-induced reinstatement of drug-seeking, though psilocybin showed a trend toward attenuation. The treatments had no side effects on general locomotor activity or anxiety-like behavior in the open field test. These results suggest psilocybin and ibogaine may support extinction learning and possibly protect against relapse, warranting further research into their antiaddictive potential.
Planta Medica
March 1, 2026
K Knížková, D Lovás, R Batelková et al.
The plant Tabernanthe iboga contains ibogaine, an alkaloid that helps treat addiction by easing withdrawal and reducing cravings. Because authentic T. iboga from Africa is scarce, other plants with potentially toxic alkaloids are sometimes substituted, leading to fatal overdoses. This study developed an HPLC-MS method to analyze 11 iboga alkaloids and their derivatives, testing different extraction solvents; ethyl acetate with ammonium hydroxide worked best. Real samples from ibogaine clinics were analyzed to assess quality control and risks. The method aims to distinguish T. iboga from plants that might be used to falsify it, improving safety.